KARO BIO PUBLISHES ANNUAL REPORT

Karo Bio’s Annual Report 2013 has been published and is available on the
company’s website www.karobio.se.


For further information, please contact:
Henrik Palm, CFO, mobile phone +46 70-540 40 14 or e-mail henrik.palm@karobio.se



About Karo Bio
Karo Bio is a research and development company focused on innovative drugs for
important medical needs. The world-leading knowledge of nuclear receptors as
target proteins for the development of pharmaceuticals and their related
mechanisms of action, are utilized for developing novel, more effective and
safer pharmaceuticals. Karo Bio is active in preclinical development focused on
the areas of neuropsychiatry, inflammation, autoimmune diseases and cancer. Karo
Bio is based in Huddinge, Sweden. The company has around 39 employees and is
listed on NASDAQ OMX Stockholm.

This press release is also available online at www.karobio.com and
www.newsroom.cision.com.